
US-based pharmaceutical company MSD has stopped a trial of its prostate cancer treatment candidate. The trial in question is a combination trial of MSD’s Keytruda and Astrazeneca’s Lynparza.
The trial has been stopped as preliminary data did not show that the drug had any effect on survival rates.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app